|
US4690915A
(en)
|
1985-08-08 |
1987-09-01 |
The United States Of America As Represented By The Department Of Health And Human Services |
Adoptive immunotherapy as a treatment modality in humans
|
|
US6352694B1
(en)
|
1994-06-03 |
2002-03-05 |
Genetics Institute, Inc. |
Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
|
|
US6534055B1
(en)
|
1988-11-23 |
2003-03-18 |
Genetics Institute, Inc. |
Methods for selectively stimulating proliferation of T cells
|
|
US6905680B2
(en)
|
1988-11-23 |
2005-06-14 |
Genetics Institute, Inc. |
Methods of treating HIV infected subjects
|
|
US5858358A
(en)
|
1992-04-07 |
1999-01-12 |
The United States Of America As Represented By The Secretary Of The Navy |
Methods for selectively stimulating proliferation of T cells
|
|
US5585362A
(en)
|
1989-08-22 |
1996-12-17 |
The Regents Of The University Of Michigan |
Adenovirus vectors for gene therapy
|
|
US5350674A
(en)
|
1992-09-04 |
1994-09-27 |
Becton, Dickinson And Company |
Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
|
|
US7175843B2
(en)
|
1994-06-03 |
2007-02-13 |
Genetics Institute, Llc |
Methods for selectively stimulating proliferation of T cells
|
|
US5874540A
(en)
|
1994-10-05 |
1999-02-23 |
Immunomedics, Inc. |
CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
|
|
US7067318B2
(en)
|
1995-06-07 |
2006-06-27 |
The Regents Of The University Of Michigan |
Methods for transfecting T cells
|
|
US6692964B1
(en)
|
1995-05-04 |
2004-02-17 |
The United States Of America As Represented By The Secretary Of The Navy |
Methods for transfecting T cells
|
|
WO1999043817A1
(en)
|
1998-02-25 |
1999-09-02 |
The Dow Chemical Company |
High affinity humanized anti-cea monoclonal antibodies
|
|
PL209392B1
(pl)
*
|
1999-01-15 |
2011-08-31 |
Genentech Inc |
Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
|
|
HK1047109A1
(zh)
|
1999-10-15 |
2003-02-07 |
University Of Massachusetts |
作为指定基因干预工具的rna干预轨迹基因
|
|
US6326193B1
(en)
|
1999-11-05 |
2001-12-04 |
Cambria Biosciences, Llc |
Insect control agent
|
|
US7572631B2
(en)
|
2000-02-24 |
2009-08-11 |
Invitrogen Corporation |
Activation and expansion of T cells
|
|
US6797514B2
(en)
|
2000-02-24 |
2004-09-28 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
|
US6867041B2
(en)
|
2000-02-24 |
2005-03-15 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
|
KR20030032922A
(ko)
|
2000-02-24 |
2003-04-26 |
싸이트 테라피스 인코포레이티드 |
세포의 동시 자극 및 농축
|
|
AU2001275474A1
(en)
|
2000-06-12 |
2001-12-24 |
Akkadix Corporation |
Materials and methods for the control of nematodes
|
|
CA2450285C
(en)
|
2001-06-13 |
2016-08-02 |
Genmab A/S |
Human monoclonal antibodies to epidermal growth factor receptor (egfr)
|
|
US7745140B2
(en)
|
2002-01-03 |
2010-06-29 |
The Trustees Of The University Of Pennsylvania |
Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
|
|
US20030170238A1
(en)
|
2002-03-07 |
2003-09-11 |
Gruenberg Micheal L. |
Re-activated T-cells for adoptive immunotherapy
|
|
CA2559955C
(en)
|
2004-03-15 |
2016-02-16 |
City Of Hope |
Methods and compositions for the specific inhibition of gene expression by double-stranded rna
|
|
WO2005118788A2
(en)
|
2004-05-27 |
2005-12-15 |
The Trustees Of The University Of Pennsylvania |
Novel artificial antigen presenting cells and uses therefor
|
|
WO2006031221A1
(en)
|
2004-09-13 |
2006-03-23 |
Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Compositions comprising t cell receptors and methods of use thereof
|
|
US20120009162A1
(en)
|
2009-04-03 |
2012-01-12 |
Masaki Yasukawa |
T cell receptor and nucleic acid encoding the receptor
|
|
KR101528013B1
(ko)
|
2009-08-31 |
2015-06-16 |
로슈 글리카트 아게 |
친화성-성숙된 인간화된 항-ｃｅａ 단일클론 항체
|
|
PH12013501201A1
(en)
|
2010-12-09 |
2013-07-29 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
|
PE20141017A1
(es)
|
2011-03-02 |
2014-08-25 |
Roche Glycart Ag |
Anticuerpos del cea
|
|
WO2013054320A1
(en)
*
|
2011-10-11 |
2013-04-18 |
Tel Hashomer Medical Research Infrastructure And Services Ltd. |
Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
|
|
CA3285826A1
(en)
|
2012-02-22 |
2026-03-02 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer
|
|
EP2828290B1
(en)
|
2012-03-23 |
2018-08-15 |
The United States of America, represented by the Secretary, Department of Health and Human Services |
Anti-mesothelin chimeric antigen receptors
|
|
AU2013266968B2
(en)
|
2012-05-25 |
2017-06-29 |
Emmanuelle CHARPENTIER |
Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
|
|
DK3199552T3
(da)
|
2012-11-20 |
2020-03-30 |
Sanofi Sa |
Anti-ceacam5-antistoffer og anvendelser heraf
|
|
US8697359B1
(en)
|
2012-12-12 |
2014-04-15 |
The Broad Institute, Inc. |
CRISPR-Cas systems and methods for altering expression of gene products
|
|
CN113355357B
(zh)
|
2012-12-12 |
2024-12-03 |
布罗德研究所有限公司 |
对用于序列操纵的改进的系统、方法和酶组合物进行的工程化和优化
|
|
EP2840140B2
(en)
|
2012-12-12 |
2023-02-22 |
The Broad Institute, Inc. |
Crispr-Cas based method for mutation of prokaryotic cells
|
|
EP2961773B1
(en)
|
2013-02-26 |
2019-03-20 |
Roche Glycart AG |
Bispecific t cell activating antigen binding molecules
|
|
IL311390A
(en)
|
2013-03-15 |
2024-05-01 |
Memorial Sloan Kettering Cancer Center |
Preparations and methods for immunotherapy
|
|
WO2014145252A2
(en)
|
2013-03-15 |
2014-09-18 |
Milone Michael C |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
|
EP3925618A1
(en)
|
2013-07-29 |
2021-12-22 |
2seventy bio, Inc. |
Multipartite signaling proteins and uses thereof
|
|
MX373687B
(es)
|
2013-11-21 |
2020-07-07 |
Ucl Business Ltd |
Célula natural (nk)
|
|
AU2015214145A1
(en)
|
2014-02-04 |
2016-08-25 |
Kite Pharma. Inc. |
Methods for producing autologous T cells useful to treat B cell malignancies and other cancers and compositions thereof
|
|
MX2017002205A
(es)
*
|
2014-08-19 |
2017-08-21 |
Novartis Ag |
Receptor quimerico de antigeno (car) anti-cd123 para uso en el tratamiento de cancer.
|
|
WO2016075612A1
(en)
|
2014-11-12 |
2016-05-19 |
Rinat Neuroscience Corp. |
Inhibitory chimeric antigen receptors
|
|
CA2969384A1
(en)
|
2014-12-17 |
2016-06-23 |
Cellectis |
Inhibitory chimeric antigen receptor (icar or n-car) expressing non-t cell transduction domain
|
|
CN204537344U
(zh)
|
2015-01-29 |
2015-08-05 |
西门子瑞士有限公司 |
通知设备
|
|
WO2016126608A1
(en)
|
2015-02-02 |
2016-08-11 |
Novartis Ag |
Car-expressing cells against multiple tumor antigens and uses thereof
|
|
KR102624023B1
(ko)
|
2015-02-24 |
2024-01-11 |
더 리젠츠 오브 더 유니버시티 오브 캘리포니아 |
결합-촉발된 전사 스위치 및 이들의 이용 방법
|
|
JP2018509148A
(ja)
|
2015-03-11 |
2018-04-05 |
セレクティスＣｅｌｌｅｃｔｉｓ |
患者における持続性および／または生着を増加させるために同種ｔ細胞を改変する方法
|
|
AU2016243128A1
(en)
|
2015-03-27 |
2017-11-02 |
University Of Southern California |
HLA-G as a novel target for CAR T-cell immunotherapy
|
|
GB201509413D0
(en)
|
2015-06-01 |
2015-07-15 |
Ucl Business Plc |
Fusion protein
|
|
HK1255161A1
(zh)
|
2015-07-15 |
2019-08-09 |
Juno Therapeutics, Inc. |
用於过继性细胞治疗的工程细胞
|
|
BR112018008442A2
(pt)
|
2015-11-05 |
2018-11-06 |
Juno Therapeutics Inc |
receptores quiméricos contendo domínios induto-res de traf e composições e métodos relacionados
|
|
US20210206826A1
(en)
|
2015-11-19 |
2021-07-08 |
The Regents Of The University Of California |
Conditionally repressible immune cell receptors and methods of use thereof
|
|
KR20180075689A
(ko)
|
2015-11-23 |
2018-07-04 |
트르스티스 오브 보스톤 유니버시티 |
키메라 항원 수용체에 관한 방법 및 조성물
|
|
AU2016363696B2
(en)
|
2015-12-02 |
2021-05-20 |
Innovative Targeting Solutions Inc. |
Single variable domain T-cell receptors
|
|
JP2019509738A
(ja)
|
2016-03-11 |
2019-04-11 |
ブルーバード バイオ， インコーポレイテッド |
ゲノム編集された免疫エフェクター細胞
|
|
AU2017286835B2
(en)
|
2016-06-29 |
2023-12-14 |
Crispr Therapeutics Ag |
Compositions and methods for gene editing
|
|
EP3263595A1
(en)
|
2016-06-30 |
2018-01-03 |
Medizinische Hochschule Hannover |
Fusion protein for use in the treatment of hvg disease
|
|
CN109843929B
(zh)
|
2016-08-23 |
2024-07-05 |
加利福尼亚大学董事会 |
蛋白水解可切割的嵌合多肽及其使用方法
|
|
CN109996868A
(zh)
|
2016-09-23 |
2019-07-09 |
弗雷德哈钦森癌症研究中心 |
特异性用于次要组织相容性(h)抗原ha-1的tcr及其用途
|
|
BR112019006006A2
(pt)
|
2016-09-28 |
2019-06-25 |
Gavish-Galilee Bio Applications Ltd. |
molécula de ácido nucleico, vetor, métodos para preparação de um receptor de antígeno quimérico inibidor, para preparar uma célula imune efetora segura, para selecionar um biomarcador personalizado e para tratar o câncer em um paciente com um tumor, célula imune efetora segura, e, combinação de duas ou mais moléculas de ácido nucleico.
|
|
CN110582509A
(zh)
*
|
2017-01-31 |
2019-12-17 |
诺华股份有限公司 |
使用具有多特异性的嵌合t细胞受体蛋白治疗癌症
|
|
US20190359678A1
(en)
|
2017-02-09 |
2019-11-28 |
The Regents Of The University Of California |
Chimeric t cell antigen receptors and methods of use thereof
|
|
ES3010117T3
(en)
|
2017-03-27 |
2025-04-01 |
Hoffmann La Roche |
Improved antigen binding receptors
|
|
KR20190133017A
(ko)
|
2017-03-27 |
2019-11-29 |
에프. 호프만-라 로슈 아게 |
개선된 항원 결합 수용체 구성
|
|
US12378297B2
(en)
|
2017-04-14 |
2025-08-05 |
The General Hospital Corporation |
Chimeric antigen receptor T cells targeting the tumor microenvironment
|
|
JP7132249B2
(ja)
|
2017-05-15 |
2022-09-06 |
オートラス リミテッド |
キメラ抗原受容体（ｃａｒ）を含む細胞
|
|
GB201707779D0
(en)
|
2017-05-15 |
2017-06-28 |
Autolus Ltd |
Cell
|
|
GB201707783D0
(en)
|
2017-05-15 |
2017-06-28 |
Autolus Ltd |
Cell
|
|
TWI795415B
(zh)
|
2017-07-07 |
2023-03-11 |
日商安斯泰來製藥股份有限公司 |
新穎的抗人類ＣＥＡＣＡＭ５抗體Ｆａｂ片段
|
|
SG11202002520UA
(en)
*
|
2017-09-19 |
2020-04-29 |
Univ British Columbia |
Anti-hla-a2 antibodies and methods of using the same
|
|
EP3684822A4
(en)
*
|
2017-09-20 |
2021-06-16 |
The University of British Columbia |
NEW ANTI-HLA-A2 ANTIBODIES AND USES THEREOF
|
|
WO2019068007A1
(en)
|
2017-09-28 |
2019-04-04 |
Immpact-Bio Ltd. |
UNIVERSAL PLATFORM FOR PREPARING AN INHIBITORY CHIMERIC ANTIGEN RECEPTOR (ICAR)
|
|
WO2019084055A1
(en)
|
2017-10-23 |
2019-05-02 |
Massachusetts Institute Of Technology |
CLASSIFICATION OF GENETIC VARIATION FROM UNICELLULAR TRANSCRIPTOMS
|
|
EP3707166A4
(en)
|
2017-11-06 |
2021-11-24 |
Daniel J. Monticello |
CHEMICAL ANTIGENIC RECEPTOR SYSTEMS WITH NEGATIVE DOMINANT LIGAND
|
|
US11866731B2
(en)
*
|
2017-11-10 |
2024-01-09 |
Chineo Medical Technology Co., Ltd |
Modified immune cells and uses thereof
|
|
CN108219004A
(zh)
*
|
2018-02-08 |
2018-06-29 |
吉林省拓华生物科技有限公司 |
双特异嵌合抗原受体修饰的t细胞、其制备方法及用途
|
|
EP3775883A1
(en)
*
|
2018-04-04 |
2021-02-17 |
F. Hoffmann-La Roche AG |
Diagnostic assays to detect tumor antigens in cancer patients
|
|
WO2019241549A1
(en)
|
2018-06-15 |
2019-12-19 |
A2 Biotherapeutics, Inc. |
Foxp3-expressing car-t regulatory cells
|
|
BR112021006100A2
(pt)
|
2018-09-28 |
2021-07-20 |
Immpact-Bio Ltd. |
métodos para identificação de pares de receptor de antígeno ativador (acar)/receptor de antígeno quimérico inibitório (icar) para uso em terapias de câncer
|
|
WO2020070290A1
(en)
|
2018-10-05 |
2020-04-09 |
St. Anna Kinderkrebsforschung |
A group of chimeric antigen receptors (cars)
|
|
EP3632461A1
(en)
|
2018-10-05 |
2020-04-08 |
St. Anna Kinderkrebsforschung |
A group of chimeric antigen receptors (cars)
|
|
AU2020226401A1
(en)
*
|
2019-02-18 |
2021-10-14 |
Memorial Sloan-Kettering Cancer Center |
Combinations of multiple chimeric antigen receptors for immunotherapy
|
|
CN113906053B
(zh)
|
2019-06-26 |
2022-10-25 |
江苏恒瑞医药股份有限公司 |
抗cea抗体及其应用
|
|
WO2021030182A1
(en)
|
2019-08-09 |
2021-02-18 |
A2 Biotherapeutics, Inc. |
Bifunctional single variable domain t cell receptors and uses thereof
|
|
WO2021030153A2
(en)
|
2019-08-09 |
2021-02-18 |
A2 Biotherapeutics, Inc. |
Engineered t cell receptors and uses thereof
|
|
MX2022001711A
(es)
|
2019-08-09 |
2022-05-10 |
A2 Biotherapeutics Inc |
Receptores en la superficie celular que responden a la perdida de heterocigosidad.
|
|
JP2022546315A
(ja)
|
2019-08-20 |
2022-11-04 |
センティ バイオサイエンシズ インコーポレイテッド |
キメラ抑制性受容体
|
|
WO2021053587A1
(en)
|
2019-09-18 |
2021-03-25 |
Klaus Strein |
Bispecific antibodies against ceacam5 and cd3
|
|
EP4058561A1
(en)
|
2019-11-12 |
2022-09-21 |
A2 Biotherapeutics, Inc. |
Engineered t cell receptors and uses thereof
|
|
EP3831849A1
(en)
|
2019-12-02 |
2021-06-09 |
LamKap Bio beta AG |
Bispecific antibodies against ceacam5 and cd47
|
|
CN115052887B
(zh)
|
2019-12-11 |
2026-03-31 |
A2生物治疗公司 |
基于lilrb1的嵌合抗原受体
|
|
WO2021222576A1
(en)
|
2020-05-01 |
2021-11-04 |
A2 Biotherapeutics, Inc. |
Pag1 fusion proteins and methods of making and using same
|
|
WO2021252635A1
(en)
|
2020-06-11 |
2021-12-16 |
A2 Biotherapeutics, Inc. |
Compositions and methods for treating cancers
|
|
WO2022036065A2
(en)
|
2020-08-13 |
2022-02-17 |
A2 Biotherapeutics, Inc. |
Compositions and methods for treating cancers
|
|
CA3188867A1
(en)
|
2020-08-20 |
2022-02-24 |
Xueyin Wang |
Compositions and methods for treating ceacam positive cancers
|
|
WO2022040470A1
(en)
|
2020-08-20 |
2022-02-24 |
A2 Biotherapeutics, Inc. |
Compositions and methods for treating ceacam positive cancers
|
|
AU2021386366A1
(en)
*
|
2020-11-24 |
2023-06-29 |
A2 Biotherapeutics, Inc. |
Adoptive cell therapy for treatment of cancer associated with loss of heterozygosity
|